Phase II year
2022
(last award dollars: 2023)
Phase II Amount
$1,446,904
The inability to engage in spoken communication is among the most debilitating of all human conditions. In the field of communication disorders, a speech-language pathologist's (SLP's) perceptual evaluation of the quality of speech production is the gold standard for assessment and for documenting treatment progress. However, decades of research have confirmed that auditory-perceptual judgments of speech are inherently biased, which compromises reliability. The reason is that the human perceptual system is adaptive, with perceptual bias accrued by working with an individual across multiple treatment sessions, or by working with patient populations across a career. Thus, to reliably document treatment outcomes subjectively, it is necessary to involve multiple, unfamiliar listeners. This is untenable in most clinical settings, which means that subjective impressions are made by the treating clinicians. The reliance on subjective evaluation directly undermines the quality of clinical practice and a clinician's ability to demonstrate the efficacy of an intervention. Aural Analytics has developed new objective acoustic speech metrics that reliably measure speech in populations with neurological disorders. Its technology is based on a strong scientific premise and has been adopted early by pharmaceutical companies and neurologists in clinical research. Aural Analytics has collected and analyzed tens of thousands of speech samples using its technology, and the results are demonstrating that its measures are robust, reliable, and more sensitive to longitudinal changes in speech than are other existing outcome measures. We successfully completed a Phase I SBIR project with the aim of translating our technology to SLP clinical practice. This Phase II proposal naturally builds on our previous work by connecting the automated app-based outcome measures completed in Phase I to three complementary clinical benchmarks. Specifically, SA1 will validate the Aural Analytics speech measures against the American Speech-Language-Hearing Association's (ASHA) Functional Communication Measures (FCM) for motor speech; the Sentence Intelligibility Test; and expert ratings of speech characteristics. In addition, age and gender-based norms for all objective measures will be obtained from collection of data from 600 new healthy participants. In SA2, Aural Analytics will conduct a usability study with practicing speech-language pathologists to assess real world utility and refine the user experience. The deliverable of this proposal will be a fully-functional mobile application, validated by practicing SLPs in a clinical setting, with real time speech outcome metrics validated with respect to existing community-accepted measures. This will result in objective outcomes that fit into the workflow of the professional standard, thereby expediting our path to commercialization.
Public Health Relevance Statement: Project Narrative In the field of communication disorders, a speech-language pathologist's perceptual evaluation of the quality of speech production is the gold standard for assessment and for documenting treatment progress. We propose to augment the subjective evaluation of speech with a set of objective app-based outcome measures that have been shown to track clinically-relevant changes in speech production and to connect those measures to existing professional standards of communication measures for speech. We will then test the ability of this technology to fit into the workflow of the professional standard via a user study, thereby expediting our path to commercialization.
Project Terms: improved; Clinical; Phase; Evaluation; insight; Individual; Neurologist; participant recruitment; Patient Recruitments; Pathologist; Adopted; Auditory; System; Best Practice Analysis; Benchmarking; interest; experience; impression; Performance; Familiarity; HIPAA; Kennedy Kassebaum Act; PL 104-191; PL104-191; Public Law 104-191; United States Health Insurance Portability and Accountability Act; Health Insurance Portability and Accountability Act; Participant; Position; Positioning Attribute; Sampling; Intervention Strategies; interventional strategy; Intervention; Pharmaceutical Agent; Pharmaceuticals; Pharmacological Substance; Pharmacologic Substance; Data; Motor; Small Business Innovation Research Grant; SBIR; Small Business Innovation Research; Update; Characteristics; Development; developmental; Treatment Efficacy; intervention efficacy; therapeutic efficacy; therapy efficacy; Outcome; Population; prospective; Impairment; clinically relevant; clinical relevance; usability; commercialization; patient population; clinical practice; mobile application; mobile app; mobile device application; professional atmosphere; job environment; work atmosphere; work environment; workplace climate; workplace environment; crowdsourcing; crowd source; crowd-sourcing; crowdsource; recruit; Infrastructure; clinical outcome measures; Acoustics; Acoustic; Age; ages; Clinical Research; Clinical Study; Communication; Communication impairment; Communication Disorders; Communicative Disorders; Communities; Data Collection; Dysarthria; Dysarthosis; Feedback; Patient Care; Patient Care Delivery; Gold; Health; Human; Modern Man; Interview; Judgment; Language; Learning; Nervous System Diseases; Neurologic Disorders; Neurological Disorders; neurological disease; nervous system disorder; Patients; Population Distributions; Production; Regression Analyses; Regression Diagnostics; Statistical Regression; Regression Analysis; Research; Research Resources; Resources; Software; Computer software; Speech; Speech Acoustics; Speech Manifestations; Speech Disorders; Speech Intelligibilities; Speech Intelligibility; Speech Therapy; statistics; Survey Instrument; Surveys; Technology; Testing; thoughts; Thinking; Time; Translating; Work; American Speech-Language-Hearing Association; Gender; Measures; Treatment outcome; Outcome Measure; Secondary to; base; career; Loudness